Background: There is no agreed upon definition of systemic corticosteroid response in asthmatic children. Moreover, pediatric severe therapy-resistant asthma (STRA) is heterogeneous, and thus response to steroids is unlikely to be uniform in all patients. Objective: We sought to evaluate the utility of a multidomain approach incorporating symptoms, lung function, and inflammation to determine steroid responsiveness in pediatric patients with STRA. Methods: Eighty-two children (median age, 12 years) with STRA received a clinically indicated dose of intramuscular steroid. Changes in 4 separate domains were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (Asthma Control Test score, >19/25 or 50% increase), (2) spirometric results (FEV 1 > _80% of predicted value or > _15% increase), (3) fraction of exhaled nitric oxide levels (<24 ppb), and (4) sputum eosinophil counts (<2.5%). Fifty-four of 82 children had complete data in all 4 domains. Results: Twenty-three (43%) of 54 children had a symptom response, 29 (54%) of 54 had a lung function response, 28 (52%) of 54 had a fraction of exhaled nitric oxide response, and 29 (54%) of 54 had a sputum eosinophil response. Although a similar proportion of children responded to systemic corticosteroids in each domain, there were no reliable predictors of a response pattern. Seven (13%) of 54 were complete responders (response in all domains), 8 (15%) of 54 were nonresponders (no response in any domain), and 39 (72%) of 54 were partial responders (response in > _1 domain).
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Background: There is no agreed upon definition of systemic corticosteroid response in asthmatic children. Moreover, pediatric severe therapy-resistant asthma (STRA) is heterogeneous, and thus response to steroids is unlikely to be uniform in all patients. Objective: We sought to evaluate the utility of a multidomain approach incorporating symptoms, lung function, and inflammation to determine steroid responsiveness in pediatric patients with STRA. Methods: Eighty-two children (median age, 12 years) with STRA received a clinically indicated dose of intramuscular steroid. Changes in 4 separate domains were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (Asthma Control Test score, >19/25 or 50% increase), (2) spirometric results (FEV 1 > _80% of predicted value or > _15% increase), (3) fraction of exhaled nitric oxide levels (<24 ppb), and (4) sputum eosinophil counts (<2.5%). Fifty-four of 82 children had complete data in all 4 domains. Results: Twenty-three (43%) of 54 children had a symptom response, 29 (54%) of 54 had a lung function response, 28 (52%) of 54 had a fraction of exhaled nitric oxide response, and 29 (54%) of 54 had a sputum eosinophil response. Although a similar proportion of children responded to systemic corticosteroids in each domain, there were no reliable predictors of a response pattern. Seven (13%) of 54 were complete responders (response in all domains), 8 (15%) of 54 were nonresponders (no response in any domain), and 39 (72%) of 54 were partial responders (response in > _1 domain).
Conclusions: A multidomain evaluation of systemic steroid responsiveness using pragmatic clinical assessments confirms childhood STRA is heterogeneous and that a complete response in symptoms and inflammatory and physiologic parameters is rare. Individual response patterns to systemic steroids might be useful in guiding the choice of add-on therapies in each child as a step toward achieving personalized medicine. (J Allergy Clin Immunol 2016;138:413-20.)
Key words: Pediatric, severe asthma, steroid response, spirometry, inflammation Approximately 2% to 5% of all asthmatic children have severe therapy-resistant asthma (STRA), are challenging to treat, and consume significant health care resources. 1 Many children can have asthma that is difficult to treat despite high doses of therapy because of previously unidentified modifiable factors, such as poor adherence or persistent allergen exposure. 2 However, once these basic factors have been addressed, a group with STRA remains. 3 The mainstay of asthma treatment is inhaled corticosteroids (ICSs). However, children with STRA have disease that remains poorly controlled despite high doses of ICSs; additional controllers, such as long-acting b 2 -agonists and leukotriene receptor antagonists; and often maintenance oral steroid therapy. Steroid responsiveness can be measured in many ways, but currently, there is no accepted definition in children. A proposed definition of steroid response 4, 5 is a 15% or greater predicted increase in morning FEV 1 in patients with bronchodilator reversibility (BDR) of 12% or greater from baseline and an abnormal FEV 1 (<80% of predicted value) before a systemic steroid trial. However, it is acknowledged that this might not be an appropriate definition for children because many children with a confirmed diagnosis of severe asthma have normal spirometric results, but their symptoms remain poorly controlled. [6] [7] [8] We have previously shown pediatric STRA to be heterogeneous with respect to lung function, inflammation, and remodeling. 3 Although, as a group, children with STRA have lower lung function, increased eosinophilic inflammation, and increased reticular basement membrane thickness and smooth muscle mass compared with patients with mild asthma and nonasthmatic control subjects, 3 there is overlap between groups, as well as considerable variability within patients with STRA. Given this marked variation within the STRA group, it is likely that some children might respond more to steroids with an improvement in lung function, whereas others might only show a response through an improvement in inflammation. Therefore we investigated a multidomain definition of systemic corticosteroid responsiveness, namely change in (1) symptoms, (2) spirometry, and (3) noninvasive markers of inflammation before and 4 weeks after a single clinically indicated dose of intramuscular triamcinolone acetonide. We hypothesized that children with STRAwould not have a uniform response pattern. We also related the steroidresponse pattern to clinical features and peripheral and airway inflammation before administering the systemic steroid to try to identify predictors of response pattern.
METHODS

Subjects and definition of severe asthma (STRA)
Children aged between 6 and 16 years with problematic severe asthma (ongoing poor control despite prescribed high-dose inhaled steroids [> _800 mg/d], additional controller medications, and assignment to stage 4/5 of the British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines) referred between 2005 and 2012 were investigated by using our standardized clinical investigation protocol with an outpatient-led nurse assessment and home visit. 2, 3 Children with modifiable factors that could be addressed, in particular adherence, were classified as having difficult asthma and excluded from this study (Fig 1) . 9 Only the remaining patients, in whom diagnosis had been confirmed (evidence of reversible airflow obstruction and doctor-diagnosed wheeze), adherence had been ensured (general practitioner prescription records, appropriate inhalers being available during the home visit, and proved ability to use the medication delivery device prescribed), and underlying modifiable factors (eg, environmental tobacco smoke and allergen exposure) had been minimized, were given a diagnosis of STRA, which is in line with recent guidelines. 10 All children with STRA underwent our clinical protocol, which includes bronchoscopy, as previously described, 3 followed by a single intramuscular injection of triamcinolone acetonide to determine steroid responsiveness. This was a clinical investigation protocol but not a clinical trial. The intramuscular steroid preparation used (triamcinolone acetonide [Kenalog]; Bristol-Meyers Squibb, New York, NY) was recommended for sustained systemic corticosteroid treatment in patients with asthma 11 and has previously been used in adults 12 and children 13 with difficult asthma. A single dose of intramuscular systemic steroids was administered, and assessments of steroid response were made immediately before and 4 weeks after administration.
Bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy
Bronchoscopy and bronchoalveolar lavage (BAL) were performed after achievement of general anesthesia, and samples were processed for analysis of eosinophilic inflammation, as previously described (see the Methods section in this article's Online Repository at www.jacionline.org for details). 3 Blood for total IgE and eosinophil measurements was taken at the time of bronchoscopy.
Administration of systemic steroid and assessments of steroid response
An assessment with the (1) the Asthma Control Test (ACT) for symptom control (see Fig E1 in this article's Online Repository at www.jacionline.org), (2) spirometry, 14 (3) sputum eosinophil measurement, and (4) fraction of exhaled nitric oxide (FENO; at a flow rate of 50 mL/s) measurement was made on the morning of bronchoscopy. An intramuscular injection of triamcinolone acetonide (80 mg at age > _12 years and 40 mg at age <12 years) 13 was administered at the end of the bronchoscopy, and tests 1 to 4 were repeated 4 weeks later to determine steroid response (Table I) .
Multidomain definition of steroid response
Some children had normal values for some domains before receiving the systemic corticosteroid. Thus they did not have steroid-unresponsive abnormalities in those domains. Because all children were already prescribed high-dose maintenance inhaled steroids and we had ensured adherence as far as possible, we assumed those with normal values before the systemic corticosteroid trial that remained normal in that domain were steroid responsive. We believed in these children it was unethical to confirm this by reducing their treatment until abnormalities appeared in all domains. Therefore data analysis was initially undertaken for all patients. Subsequently, the analysis was restricted to include only those children whose symptoms did not improve after triamcinolone (ie, abnormal at baseline) to assess additional responsiveness after systemic corticosteroids. Response to steroids was examined in each domain and in a combination of domains.
Symptom (ACT) response. Symptom control was assessed by using the ACT 15 because most patients were 12 years or older, and for consistency, this was used in preference to the childhood ACT, which was not available at the start of data collection. A positive response was defined as an ACT score of greater than 19 of 25 16 or an increase of 50% or greater.
FEV 1 response. Spirometry was performed according to American
Thoracic Society/European Respiratory Society guidelines. 14 Response was defined as attaining a prebronchodilator FEV 1 of 80% of predicted value or greater or an increase of 15% or greater.
FENO response. FENO measurements at 50 mL/s were made with a chemiluminescence analyzer (NIOX; Aerocrine, Solna, Sweden) in accordance with American Thoracic Society/European Respiratory Society guidelines. 17 Response was defined as a normal value (<24 ppb).
18
Sputum eosinophil response. Sputum induction was performed with 3.5% saline, as previously described. 3 Sputum response was defined as normalization of sputum eosinophil counts (<2.5%). 19 Complete response, partial response, and nonresponse to triamcinolone acetonide A complete corticosteroid response was defined as symptom, FEV 1 , sputum eosinophil, and FENO responses. A response in at least 1 domain was a partial response, and an absence of response in all domains was nonresponse. If sputum was unavailable, responses were assessed in 3 domains only.
Statistical analysis
Baseline values for all domains in the discovery and validation cohorts were not normally distributed and were therefore analyzed by using nonparametric tests. The Mann-Whitney U test was used for continuous variables, and categorical data were analyzed by using the Fisher exact or x 2 tests. Data were analyzed by using the Wilcoxon test for nonparametric data and the paired t test for parametric data to compare changes before and after triamcinolone. Data were analyzed with SPSS, version 17 (SPSS, Chicago, Ill). Logistic regression analysis was performed, and the results were presented for univariate analysis with the statistical software Stata, version 12.1 (StataCorp, College Station, Tex).
RESULTS
Subjects and demographics
Eighty-two (51 male) children (median age, 12 years; range, 6.5-17.3 years) underwent investigations and received systemic corticosteroids (Fig 1) . All children had data for at least 1 steroidresponse domain (symptoms, FEV1, FENO, and/or sputum eosinophils), and a subgroup of 54 (37 male) children had data for all 4 domains before and after systemic steroid injection (Table II) .
Assessments of steroid response
The response pattern in each domain for all children (n 5 82) and the subgroup of children with data available in all 4 domains (n 5 54), including those with a normal value at baseline, are summarized in Fig 2 and Table III . There was no significant difference in the proportion of children who responded in each domain when all patients were compared with those who had data available for all domains.
Response pattern in each domain in children with data for all 4 parameters (n 5 54)
Only those children with a response recorded in all 4 domains (a complete data set recorded) were assessed in detail both for patterns of response and predictors of response to prevent any chance of selection bias influencing the results.
Symptom response
Twenty-three (43%) of 54 children had an improvement in symptoms after systemic corticosteroids (Fig 2, A, and Table III) .
Eight (15%) of 54 children had a normal ACT score before the steroid trial, and 16 (35%) of 46 of those with an abnormal ACT score at baseline improved or normalized (Fig 2, B) .
FEV 1 response
Twenty-nine (54%) of 54 children were steroid responsive in the FEV 1 domain (Fig 2, C, and Table III) . Twenty (37%) of 54 had normal FEV 1 (> _80% predicted) before systemic corticosteroids (as explained by their maintenance high-dose inhaled steroid therapy). Fourteen of (41%) 34 of those with an abnormal FEV 1 (<80%) at baseline showed improvement after systemic corticosteroids (Fig 2, D) .
FENO response
Twenty-eight (52%) of 54 children had normal FENO levels after systemic corticosteroids (Fig 2, E, and Table III) . Fifteen (28%) of 52 had a normal FENO level before systemic steroids, and 17 (46%) of 37 of those with an increased FENO level at baseline had a reduction to normal levels after systemic steroids (Fig 2, F) .
Sputum eosinophil response
Fifty-four children had paired sputum samples before and after triamcinolone acetonide. Of these, 29 (54%) of 54 had sputum eosinophil counts of less than 2.5% after triamcinolone acetonide (Fig 2, G, and Table III) . Fifteen (28%) of 54 had normal sputum eosinophil counts before triamcinolone. Seventeen of (44%) 39 patients who started with an abnormal sputum eosinophil count had normalization of sputum eosinophil counts after triamcinolone acetonide (Fig 2, H) . 
Discordance in FENO and sputum eosinophil domains
There was concordance in 39 (72%) of 54 children for FENO or sputum response. Twenty-one of 54 were responders in both domains, and 18 of 54 were nonresponders in both domains. There was discordance in 15 (28%) of 54 children; 7 of 54 had a FENO but not a sputum response, and 8 of 54 had a sputum but not a FENO response. Relationships between invasive and noninvasive assessments of airway eosinophils (FENO values and sputum and BAL eosinophil counts) are shown in Figs E2-E4 in this article's Online Repository at www.jacionline.org.
Complete responders, partial responders, and nonresponders
Seven (13%) of 54 children responded in all domains (complete responders), 39 (72%) of 54 responded in at least 1 domain (partial responders), and 8 (15%) of 54 did not respond in any domain (nonresponders).
Medications
There were no significant differences in response to triamcinolone in any domain between those children prescribed and not prescribed maintenance oral steroids nor was there any ICS dose effect. We do not have data concerning duration of prescribed controller therapy, but children had all been symptomatic for many years (median, 8.48 years; range, 2.3-14.5 years).
Comparison with current definitions of systemic steroid responsiveness
A definition of 15% of predicted value or greater increase in FEV 1 in patients with a BDR of 12% or greater from baseline and an abnormal FEV 1 (<80% predicted) was only applicable to 25 (46%) of 54 children because the remainder had an FEV 1 of greater than 80%, a BDR of less than 12%, or both before administration of triamcinolone acetonide. Of these patients, 12 (48%) of 25 had a positive steroid response.
Relationship between steroid-response pattern and clinical features and airway inflammation before systemic steroid injection There were no consistent clinical or inflammatory features at baseline associated with a response to systemic corticosteroids in any of the 4 domains (Table IV) . A lower ACT score (indicating more symptoms) before systemic steroids was associated with a poor response in the symptom domain (P 5 .0002). A history of intubation was associated with a better response in the FEV 1 domain, and this held true when logistic regression analysis was performed. A past history of intubation was associated with a response in the FEV 1 domain, with an odds ratio of 7.02 (95% CI, 1.4-35.8; P 5 .019; see Table E1 in this article's Online Repository at www.jacionline.org). However, atopy, serum IgE levels, and blood or BAL eosinophil counts were not associated with any pattern of steroid response (Table IV) . 
DISCUSSION
We have proposed here that systemic corticosteroid response should be assessed in multiple domains, including normalization or improvement of spirometric results, symptom scores, and inflammation (sputum eosinophil counts, FENO levels, or both) in children with severe asthma because this approach reflects disease heterogeneity. None of these domains was abnormal in every child with STRA, underscoring the need for a multidomain assessment. A similar number of children (approximately 40% to 50%) responded in each domain, with no clinical features of J ALLERGY CLIN IMMUNOL VOLUME 138, NUMBER 2 a response pattern being apparent. Very few children with STRA (13%) were complete responders to triamcinolone, and a similar number (15%) were nonresponders. The majority showed a response (72%) in at least 1 domain. This is the first time a multidomain approach has been proposed for an assessment of steroid response in patients with severe asthma. Because many children with STRA have normal spirometric results despite significant symptoms, 20 exacerbations, or both, an alternative definition to that currently used in adults is needed. In support of this, the current proposed definition of systemic corticosteroid response that incorporates a baseline FEV 1 of greater than 80% of predicted value could not be applied to 50% of our children with STRA because baseline FEV 1 measurements were 80% or greater of predicted value. Many children had normal results in any 1 domain before the steroid trial. However, given the use of high-dose inhaled steroids by all children and our assessments to ensure adherence, we assumed that normal values before the systemic corticosteroid trial suggested steroid response was present in that domain or at least that the child was not steroid unresponsive in that domain.
The advantage of the proposed multidomain approach is that it allows for the recognized heterogeneity within STRA in children, 3, 21, 22 which was confirmed by the fact that a similar number of children responded in each domain and no single domain had a majority response. We related both clinical and inflammatory features to response to steroids. However, consistent associations were difficult to identify and also reflect the heterogeneity of the group.
To our knowledge, this is the first report of systemic corticosteroid responsiveness in children with true STRA. We have ensured, as far as possible, that underlying modifiable factors were identified and addressed before inclusion of subjects.
2,3 A weakness of previous reports of systemic corticosteroid responsiveness in children was the clinical mix of patients, including those with ''difficult asthma'' with underlying modifiable factors and genuine STRA. 9 Another significant improvement on previous reports 5, 6 is the use of an intramuscular steroid to ensure adherence.
We speculate that this multidomain approach can usefully be applied clinically when considering outcomes expected from addon therapies used as steroid-sparing agents in the individual child. For example, if a child has a systemic corticosteroid response in an inflammatory domain, specifically a sputum eosinophil response, then they might benefit from a trial of an mAb to IL-5, provided it can be shown that this is the pathway driving airway eosinophilia. However, if they have a lung function response, then an agent, such as an mAb to IL-13, might be a better choice because clinical trials have shown benefit in FEV 1 , 23 and mechanistically, IL-13 induces airway hyperresponsiveness. 24 This approach of choosing an add-on therapy is of particular relevance to children because blood eosinophil counts cannot always be used as a reliable marker of airway eosinophils in pediatric patients with STRA, 25 and serum periostin cannot be used as a biomarker to predict response to anti-IL-13 antibody because it is produced from bone during growth and development. 26 Omalizumab is currently the only licensed add-on therapeutic for children with STRA, but as newer biologicals become available, it might be possible to predict which one should be used in which patient by assessing the domain-specific steroid-response phenotype. The efficacy of this approach needs to be confirmed prospectively.
A limitation of our multidomain assessment was incomplete data in each domain for all 82 children. This is particularly relevant to sputum cytology because obtaining samples from children can be difficult. However, our success rate for sputum induction was approximately 80%, which is similar to that in previous pediatric reports. 27, 28 To overcome this difficulty, we included FENO as an alternative noninvasive inflammatory marker. We accept that the 2 cannot be used interchangeably, and therefore both domains were analyzed separately. 29 We acknowledge that sputum eosinophil counts vary unpredictably over time, but we submit that if the sputum eosinophil count remains increased despite parenteral corticosteroids, then the process driving sputum eosinophilia is steroid responsive, and this is the case irrespective of whether sputum eosinophil counts decrease subsequently. We also acknowledge the limitations of longitudinal FENO measurements. 30, 31 However, because this is currently the only noninvasive test of inflammation that can be performed reliably and repeatedly in children and because we were looking for a change in values over time 32, 33 rather than absolute values, we considered this a reasonable alternative. To avoid bias in the patterns of steroid response reported, we have presented data for the 54 patients in whom all parameters were available before and after the triamcinolone acetonide injection separately. However, there were no significant differences in the proportion of children who responded in each domain.
What remained uncertain with our initial approach was whether complete normalization in each domain after a single triamcinolone dose should be expected or whether a fixed improvement of greater than 50% might be more appropriate. The relatively large number (45%) of children with persistent eosinophilic airway inflammation after a single injection of Data are presented as median (range) differences before and after triamcinolone, as assessed by using the Wilcoxon test. FENO, FENO at a flow rate of 50 mL/s.
triamcinolone and the large number of atopic nonresponders suggested that 1 dose might not be enough to determine a complete response, even though we had given the recommended high dose. 34 We have given a subgroup of patients up to 3 consecutive monthly injections, but additional injections did not alter the response pattern seen after the first injection (data not shown). We acknowledge that our definition of a response in each domain was arbitrary because we accepted a 50% improvement in symptoms as a response, but for lung function and the inflammatory domains, only normalization was accepted. It is difficult to know whether systemic corticosteroid ''resistance'' is a true entity in children, 35 and it is likely that it is a spectrum, other than in those rare children with mutations in the corticosteroid receptor gene. 36 Clearly, mechanistic data are required in the future to further understand steroid resistance in children, but an essential prerequisite to such studies is a definition in children, which is the purpose of this article.
In summary, we propose a novel multidomain approach to identifying the systemic corticosteroid-response pattern in children with STRA because 50% do not meet the criteria for definitions of steroid response encompassing lung function alone. Using this approach, we have shown that approximately 40% to 50% of children respond in each domain, with little evidence of single clinical predictors of a response in a specific domain. This approach allows us to capture systemic corticosteroid responsiveness in a more phenotype-specific way, which will be the basis of future mechanistic studies and, we speculate, will help identify optimal add-on therapies. Values are presented as n/number tested or median (range), as indicated. Differences were analyzed with the Mann-Whitney U or x 2 tests.
METHODS Subjects
Children older than 5 years referred to the Royal Brompton Hospital with problematic severe asthma between April 2005 and June 2012 were initially investigated by using the difficult asthma protocol, as shown in the CONSORT diagram (Fig 1) . The diagnosis of problematic severe asthma was defined as follows:
1. persistent (most days for >3 months) chronic symptoms (use of short-acting b 2 -agonists >3/wk) of airway obstruction despite high ICS doses (> _800 mg/d budesonide equivalent) and/or regular oral corticosteroids, long-acting b 2 -agonists, and current (or previous failed trial of) montelukast OR 2. recurrent severe exacerbations requiring more than 1 admission to the intensive care unit, more than 2 hospital admissions requiring intravenous medications, or 2 or more courses of oral corticosteroids in the past year despite therapy for persistent symptoms as described in (1) above OR 3. at least 1 very sudden (< _6 hours) severe attack (requiring hospitalization) without warning despite therapy for persistent symptoms, as described in (1) above.
After assessment, E1 those reclassified as having difficult asthma were excluded. The remaining patients with STRA were further investigated.
Ethics
The study was approved by the local research ethics committee, with all procedures performed after obtaining written informed parental consent and age-appropriate child assent.
Atopic status
Atopy was defined as 1 or more positive serum specific IgE measurements or skin prick test responses to aeroallergens. Quantification of atopy was made by summing the results of specific IgE levels to cat, dog, house dust mite, tree, grass, and Aspergillus species allergens.
Asthma control
Asthma control was assessed by using the ACT (Fig E1) . A score of 20 or greater was taken to represent adequate control.
E2
Spirometry and BDR
Spirometry was performed with a Compact Vitalograph 2120 (Vitalograph, Maid, Moreton, United Kingdom) before and 15 minutes after administration of 1 mg of salbutamol through a large-volume spacer. BDR was defined as a greater than 12% change from baseline FEV 1 .
Sputum induction and analysis
Sputum was induced by means of inhalation of an aerosol of 3.5% nebulized hypertonic saline if FEV 1 was 65% of predicted value or greater after pretreatment with 1 mg of salbutamol through a large-volume spacer device. E3 If FEV 1 was less than this or the subject had previously been unable to tolerate hypertonic saline, then normal saline was used. Nebulizations of 5-minute intervals were performed up to 20 minutes or until an adequate sample was produced. Spirometry was performed after each expectoration to check that the FEV 1 had not decreased by 20% or greater from baseline, in which case the child would be given a further dose of salbutamol, and the procedure was stopped. 
